Resultats de la cerca - Alan Nicholas

  • Mostrar 1 - 7 resultats de 7
Refinar resultats
  1. 1
    Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

    Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial per Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study per Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Nuhad K. Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P. Kirschbrown, Priya Kumthekar

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

    Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 per Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann‐Lii Cheng, Norelle R. Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, В. В. Бредер

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)

    Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) per Herbert I. Hurwitz, Benjamin Tan, James A. Reeves, Henry Xiong, Brad Somer, Heinz‐Josef Lenz, Howard S. Höchster, Frank A. Scappaticci, John F. Palma, Richard Price, John J. Lee, Alan Nicholas, Nicolas Sommer, Johanna C. Bendell

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma per Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

    Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant thera... per Valerie W. Rusch, Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura, Dan J. Raz, Karen L. Reckamp, Robert E. Merritt, Dwight H. Owen, David J. Finley, Ciaran McNamee, Justin D. Blasberg, Edward B. Garon, John D. Mitchell, Robert C. Doebele, Frank A. Baciewicz, Misako Nagasaka, Harvey I. Pass, Katja Schulze, Ann Johnson, Paul A. Bunn, Bruce E. Johnson, Mark G. Kris, David J. Kwiatkowski, Ignacio I. Wistuba, Jamie E. Chaft, David P. Carbone, Jay M. Lee

    Publicat 2022
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

    Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial per Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michał Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica M. Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric M. Toloza, Eric B. Haura, Ciaran McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David Ross Camidge, Jennifer W. Carlisle, Justin D. Blasberg

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: